Shield Therapeutics (LON:STX) Hits New 52-Week High – Here’s What Happened

Shares of Shield Therapeutics plc (LON:STX) hit a new 52-week high during mid-day trading on Wednesday . The stock traded as high as GBX 12.46 and last traded at GBX 11.80, with a volume of 17543684 shares traded. The stock had previously closed at GBX 11.20.

Wall Street Analysts Forecast Growth

Separately, Peel Hunt reissued a “buy” rating and issued a GBX 15 target price on shares of Shield Therapeutics in a research report on Friday, November 7th. One research analyst has rated the stock with a Buy rating, According to MarketBeat.com, Shield Therapeutics presently has a consensus rating of “Buy” and a consensus target price of GBX 15.

Shield Therapeutics Stock Up 5.4%

The stock has a 50 day moving average price of GBX 7.55 and a 200 day moving average price of GBX 5.62. The company has a market capitalization of £125.29 million, a P/E ratio of -5.90 and a beta of 1.42. The company has a debt-to-equity ratio of 3,691.50, a quick ratio of 2.16 and a current ratio of 1.05.

Shield Therapeutics Company Profile

Shield is a commercial-stage specialty pharmaceutical company that delivers Accrufer®/Feraccru® (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company has launched Accrufer® in the U.S.